Literature DB >> 29424891

Autophagy suppresses the proliferation of renal carcinoma cell.

Z-L Wang1, Q Deng, T Chong, Z-M Wang.   

Abstract

OBJECTIVE: To investigate the effetcs of autophagy on the proliferation of renal carcinoma (RCCs).
MATERIALS AND METHODS: Authophagy related protein 7 (Atg7)-overexpressing and knockdown RCC cell lines were established using lentiviral transfection and shRNA interference, respectively. (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (MTT) was used to determine the Cell growth rate, and western blot was used to determine the expression of protein. In order to establish xenograft animal models, stable transfected cells were injected into nude mice. After that those mice were used to detect the effect of autophagy on the growth of RCC in vivo.
RESULTS: Atg7 overexpression could up-regulate the level of LC3II in RCC cell lines, while Atg7-knockdown suppressed the expression of light chain 3 II (LC3II) in RCC cell lines. Atg7-overexpression cells exhibited a decreased growth profile, while suppressing the expression of Atg7 could accelerate the growth of RCC formed tumors.
CONCLUSIONS: Our data indicated that autophagy could suppress the growth of RCC cells in vivo and in vitro, and autophagy appeared to be a new therapeutic target for treating advanced renal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29424891     DOI: 10.26355/eurrev_201801_14178

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  9 in total

1.  RAC3 Inhibition Induces Autophagy to Impair Metastasis in Bladder Cancer Cells via the PI3K/AKT/mTOR Pathway.

Authors:  Liwei Wang; Jiazhong Shi; Sha Liu; Yaqin Huang; Hua Ding; Baixiong Zhao; Yuting Liu; Wuxing Wang; Jin Yang; Zhiwen Chen
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

Review 2.  Is targeting autophagy mechanism in cancer a good approach? The possible double-edge sword effect.

Authors:  Su Min Lim; Ezanee Azlina Mohamad Hanif; Siok-Fong Chin
Journal:  Cell Biosci       Date:  2021-03-20       Impact factor: 7.133

3.  Construction autophagy-related prognostic risk signature combined with clinicopathological validation analysis for survival prediction of kidney renal papillary cell carcinoma patients.

Authors:  Hongjun Fei; Songchang Chen; Chenming Xu
Journal:  BMC Cancer       Date:  2021-04-15       Impact factor: 4.430

Review 4.  Autophagy as a Vital Therapy Target for Renal Cell Carcinoma.

Authors:  Ying-Hua He; Guo Tian
Journal:  Front Pharmacol       Date:  2021-02-10       Impact factor: 5.810

5.  Perioperative Circulating Tumor Cells (CTCs), MCTCs, and CTC-White Blood Cells Detected by a Size-Based Platform Predict Prognosis in Renal Cell Carcinoma.

Authors:  Zhenlong Wang; Peng Zhang; Yue Chong; Yuquan Xue; Xiaojie Yang; Hecheng Li; Li Wang; Yaping Zhang; Qi Chen; Zhaolun Li; Li Xue; HongLiang Li; Tie Chong
Journal:  Dis Markers       Date:  2021-10-25       Impact factor: 3.434

6.  Identification of ATG7 as a Regulator of Proferroptosis and Oxidative Stress in Osteosarcoma.

Authors:  Runyi Jiang; Shaohui He; Haiyi Gong; Yao Wang; Wei Wei; Jun Chen; Jinbo Hu; Chen Ye; Shuchen LiuHuang; Saiying Jin; Haifeng Wei; Wei Xu; Jianru Xiao
Journal:  Oxid Med Cell Longev       Date:  2022-10-08       Impact factor: 7.310

7.  Primary cilium and its role in tumorigenesis.

Authors:  Hongmei Mao; Yi Sun
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-04-25

8.  Identification of an Autophagy-Related Prognostic Signature for Clear Cell Renal Cell Carcinoma.

Authors:  Mei Chen; Shufang Zhang; Zhenyu Nie; Xiaohong Wen; Yuanhui Gao
Journal:  Front Oncol       Date:  2020-05-29       Impact factor: 6.244

9.  Decreased expression of TXNIP predicts poor prognosis in patients with clear cell renal cell carcinoma.

Authors:  Yuan Gao; Jin-Chun Qi; Xiaoyu Li; Jian-Ping Sun; Hong Ji; Qing-Huai Li
Journal:  Oncol Lett       Date:  2019-11-29       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.